Clinical Trial Update: Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating eribulin mesylate in combination with intermittent erlotinib in patients with previously treated advanced non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERIBULIN MESYLATE (Eribulin mesylate)
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Eisai Inc. | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-02-14